INDUSTRY OVERVIEW
The Neurodegenerative Disease is Growing at 8.70% and is expected to reach 112Billion by 2032. Below mentioned are some of the dynamics shaping the Neurodegenerative Disease.Neurodegenerative Disease Market Size in (USD Billion) CAGR Growth Rate 8.70%
| Study Period | 2020-2032 |
| Market Size (2024): | 57Billion |
| Market Size (2032): | 112Billion |
| CAGR (2024 - 2032): | 8.70% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | North America |
www.htfmarketinsights.com
The neurodegenerative disease market focuses on therapies, diagnostics, and care for progressive conditions like Alzheimer's, Parkinson's, ALS, and Huntington's disease. Characterized by the gradual deterioration of neurons, these disorders impact memory, movement, and cognitive function. With aging populations globally, demand for effective treatments, early diagnosis, and palliative care is rising. Current market offerings include symptomatic drugs, disease-modifying treatments, and assistive technologies. Biotech and pharma firms are investing in novel approaches, including monoclonal antibodies, gene therapies, and neuroprotective agents. The market is also seeing the integration of digital biomarkers, AI-based diagnostics, and brain imaging tools for earlier and more accurate detection. Challenges include high R&D costs, clinical trial failures, and the complex nature of neurodegeneration. Public-private partnerships and patient advocacy groups are influencing funding and research agendas. The neurodegenerative disease market represents a critical healthcare frontier with profound social and economic implications worldwide.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Aging Demographics Driving Increased Alzheimer/Parkinson Prevalence
- Unsatisfactory Current Treatments Boosting Urget Need For Novel Therapies
- Advances In Biomarkers And Imaging For Early Detection
- Regulatory Incentives For Orphan And Rare Neurodegenerative Drugs
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Blood–brain Barrier Remains A Major Delivery Hurdle
- High Clinical Trial Failure Rates Creating Investment Risk
- Need For Long-term Patient Monitoring For Efficacy And Safety
- Complex Regulatory Requirements For Efficacy Demonstration
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Development of monoclonal antibody therapeutics targeting amyloid or tau
- Use of gene therapy and antisense oligonucleotides
- Exploration of microbiome–gut–brain axis therapies
- Digital biomarkers via wearables monitoring cognition and movement
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Licensing Biomarker Tools To Pharma Partners
- Partnering For Early-detection Digital Diagnostic Platforms
- Launching Neurorehabilitation Remote-care Services
- Co-developing Combination Therapy Agent Platforms
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Alzheimer's
- Parkinson's
- ALS
- Huntington's
Neurodegenerative Disease Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Hospitals
- Clinics
- Research institutions
- Long-term care
- Pharma R&D
Neurodegenerative Disease Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia-Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Biogen (USA)
- Roche (Switzerland)
- Novartis (Switzerland)
- Pfizer (USA)
- Merck (USA)
- Eli Lilly (USA)
- Johnson & Johnson (USA)
- Sanofi (France)
- AbbVie (USA)
- GSK (UK)
- Eisai (Japan)
- Takeda (Japan)
- AC Immune (Switzerland)
- Amgen (USA)
- Alector (USA)
- Denali Therapeutics (USA)
- Neurocrine Biosciences (USA)
- Sage Therapeutics (USA)
- Alzheon (USA)
Neurodegenerative Disease Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2024 |
|
Based Year Market Size (2023) |
57Billion |
|
Historical Period |
2020 to 2024 |
|
CAGR (2024 to 2032) |
8.70% |
|
Forecast Period |
2024 to 2032 |
|
Forecasted Period Market Size (2032) |
112Billion |
|
Scope of the Report |
Segmentation by Type Alzheimer's,Parkinson's,ALS,Huntington's, Segmentation by Application Hospitals,Clinics,Research institutions,Long-term care,Pharma R&D, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Biogen (USA),Roche (Switzerland),Novartis (Switzerland),Pfizer (USA),Merck (USA),Eli Lilly (USA),Johnson & Johnson (USA),Sanofi (France),AbbVie (USA),GSK (UK),Eisai (Japan),Takeda (Japan),AC Immune (Switzerland),Amgen (USA),Alector (USA),Denali Therapeutics (USA),Neurocrine Biosciences (USA),Sage Therapeutics (USA),Alzheon (USA) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Neurodegenerative Disease - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Neurodegenerative Disease Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Neurodegenerative Disease Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Neurodegenerative Disease Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Aging demographics driving increased Alzheimer/Parkinson prevalence
- 3.1.2 Unsatisfactory current treatments boosting urget need for novel therapies
- 3.1.3 Advances in biomarkers and imaging for early detection
- 3.1.4 Regulatory incentives for orphan and rare neurodegenerative drugs
-
3.2 Available Opportunities
- 3.2.1 Licensing biomarker tools to pharma partners
- 3.2.2 Partnering for early-detection digital diagnostic platforms
- 3.2.3 Launching neurorehabilitation remote-care services
- 3.2.4 Co-developing combination therapy agent
-
3.3 Influencing Trends
- 3.3.1 Development of monoclonal antibody therapeutics targeting amyloid or tau
- 3.3.2 Use of gene therapy and antisense oligonucleotides
- 3.3.3 Exploration of microbiome–gut–brain axis therapies
- 3.3.4 Digital biomarker
-
3.4 Challenges
- 3.4.1 Blood–brain barrier remains a major delivery hurdle
- 3.4.2 High clinical trial failure rates creating investment risk
- 3.4.3 Need for long-term patient monitoring for efficacy and safety
- 3.4.4 Complex regulatory re
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Neurodegenerative Disease Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Neurodegenerative Disease Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Neurodegenerative Disease : Competition Benchmarking & Performance Evaluation
- 5.1 Global Neurodegenerative Disease Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Neurodegenerative Disease Revenue 2024
- 5.3 Global Neurodegenerative Disease Sales Volume by Manufacturers (2024)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 5C’s Analysis
- 5.6 Ansoff Matrix
Chapter 6: Global Neurodegenerative Disease Market: Company Profiles
- 6.1 Biogen (USA)
- 6.1.1 Biogen (USA) Company Overview
- 6.1.2 Biogen (USA) Product/Service Portfolio & Specifications
- 6.1.3 Biogen (USA) Key Financial Metrics
- 6.1.4 Biogen (USA) SWOT Analysis
- 6.1.5 Biogen (USA) Development Activities
- 6.2 Roche (Switzerland)
- 6.3 Novartis (Switzerland)
- 6.4 Pfizer (USA)
- 6.5 Merck (USA)
- 6.6 Eli Lilly (USA)
- 6.7 Johnson & Johnson (USA)
- 6.8 Sanofi (France)
- 6.9 AbbVie (USA)
- 6.10 GSK (UK)
- 6.11 Eisai (Japan)
- 6.12 Takeda (Japan)
- 6.13 AC Immune (Switzerland)
- 6.14 Amgen (USA)
- 6.15 Alector (USA)
- 6.16 Denali Therapeutics (USA)
- 6.17 Neurocrine Biosciences (USA)
- 6.18 Sage Therapeutics (USA)
- 6.19 Alzheon (USA)
- 6.20 Cassava Sciences (USA)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Neurodegenerative Disease by Type & Application (2020-2032)
-
7.1 Global Neurodegenerative Disease Market Revenue Analysis (USD Million) by Type (2020-2024)
- 7.1.1 Alzheimer's
- 7.1.2 Parkinson's
- 7.1.3 ALS
- 7.1.4 Huntington's
- 7.1.5 MS (Multiple Sclerosis)
-
7.2 Global Neurodegenerative Disease Market Revenue Analysis (USD Million) by Application (2020-2024)
- 7.2.1 Hospitals
- 7.2.2 Clinics
- 7.2.3 Research Institutions
- 7.2.4 Long-term Care
- 7.2.5 Pharma R&D
- 7.3 Global Neurodegenerative Disease Market Revenue Analysis (USD Million) by Type (2024-2032)
- 7.4 Global Neurodegenerative Disease Market Revenue Analysis (USD Million) by Application (2024-2032)
Chapter 8 : North America Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 8.1 North America Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 8.2.1 Alzheimer's
- 8.2.2 Parkinson's
- 8.2.3 ALS
- 8.2.4 Huntington's
- 8.2.5 MS (Multiple Sclerosis)
-
8.3 North America Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 8.3.1 Hospitals
- 8.3.2 Clinics
- 8.3.3 Research Institutions
- 8.3.4 Long-term Care
- 8.3.5 Pharma R&D
- 8.4 North America Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 8.5 North America Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 8.6 North America Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 9.1 LATAM Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 9.2.1 Alzheimer's
- 9.2.2 Parkinson's
- 9.2.3 ALS
- 9.2.4 Huntington's
- 9.2.5 MS (Multiple Sclerosis)
-
9.3 LATAM Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 9.3.1 Hospitals
- 9.3.2 Clinics
- 9.3.3 Research Institutions
- 9.3.4 Long-term Care
- 9.3.5 Pharma R&D
- 9.4 LATAM Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 9.5 LATAM Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 9.6 LATAM Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 10 : West Europe Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 10.1 West Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 10.2.1 Alzheimer's
- 10.2.2 Parkinson's
- 10.2.3 ALS
- 10.2.4 Huntington's
- 10.2.5 MS (Multiple Sclerosis)
-
10.3 West Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 10.3.1 Hospitals
- 10.3.2 Clinics
- 10.3.3 Research Institutions
- 10.3.4 Long-term Care
- 10.3.5 Pharma R&D
- 10.4 West Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 10.5 West Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 10.6 West Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 11 : Central & Eastern Europe Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 11.2.1 Alzheimer's
- 11.2.2 Parkinson's
- 11.2.3 ALS
- 11.2.4 Huntington's
- 11.2.5 MS (Multiple Sclerosis)
-
11.3 Central & Eastern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 11.3.1 Hospitals
- 11.3.2 Clinics
- 11.3.3 Research Institutions
- 11.3.4 Long-term Care
- 11.3.5 Pharma R&D
- 11.4 Central & Eastern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 11.5 Central & Eastern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 11.6 Central & Eastern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 12 : Northern Europe Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 12.2.1 Alzheimer's
- 12.2.2 Parkinson's
- 12.2.3 ALS
- 12.2.4 Huntington's
- 12.2.5 MS (Multiple Sclerosis)
-
12.3 Northern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 12.3.1 Hospitals
- 12.3.2 Clinics
- 12.3.3 Research Institutions
- 12.3.4 Long-term Care
- 12.3.5 Pharma R&D
- 12.4 Northern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 12.5 Northern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 12.6 Northern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 13 : Southern Europe Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 13.2.1 Alzheimer's
- 13.2.2 Parkinson's
- 13.2.3 ALS
- 13.2.4 Huntington's
- 13.2.5 MS (Multiple Sclerosis)
-
13.3 Southern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 13.3.1 Hospitals
- 13.3.2 Clinics
- 13.3.3 Research Institutions
- 13.3.4 Long-term Care
- 13.3.5 Pharma R&D
- 13.4 Southern Europe Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 13.5 Southern Europe Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 13.6 Southern Europe Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 14 : East Asia Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 14.1 East Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 14.2.1 Alzheimer's
- 14.2.2 Parkinson's
- 14.2.3 ALS
- 14.2.4 Huntington's
- 14.2.5 MS (Multiple Sclerosis)
-
14.3 East Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 14.3.1 Hospitals
- 14.3.2 Clinics
- 14.3.3 Research Institutions
- 14.3.4 Long-term Care
- 14.3.5 Pharma R&D
- 14.4 East Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 14.5 East Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 14.6 East Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 15 : Southeast Asia Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 15.2.1 Alzheimer's
- 15.2.2 Parkinson's
- 15.2.3 ALS
- 15.2.4 Huntington's
- 15.2.5 MS (Multiple Sclerosis)
-
15.3 Southeast Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 15.3.1 Hospitals
- 15.3.2 Clinics
- 15.3.3 Research Institutions
- 15.3.4 Long-term Care
- 15.3.5 Pharma R&D
- 15.4 Southeast Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 15.5 Southeast Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 15.6 Southeast Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 16 : South Asia Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 16.1 South Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 16.2.1 Alzheimer's
- 16.2.2 Parkinson's
- 16.2.3 ALS
- 16.2.4 Huntington's
- 16.2.5 MS (Multiple Sclerosis)
-
16.3 South Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 16.3.1 Hospitals
- 16.3.2 Clinics
- 16.3.3 Research Institutions
- 16.3.4 Long-term Care
- 16.3.5 Pharma R&D
- 16.4 South Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 16.5 South Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 16.6 South Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 17 : Central Asia Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 17.1 Central Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 17.2.1 Alzheimer's
- 17.2.2 Parkinson's
- 17.2.3 ALS
- 17.2.4 Huntington's
- 17.2.5 MS (Multiple Sclerosis)
-
17.3 Central Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 17.3.1 Hospitals
- 17.3.2 Clinics
- 17.3.3 Research Institutions
- 17.3.4 Long-term Care
- 17.3.5 Pharma R&D
- 17.4 Central Asia Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 17.5 Central Asia Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 17.6 Central Asia Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 18 : Oceania Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 18.1 Oceania Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 18.2.1 Alzheimer's
- 18.2.2 Parkinson's
- 18.2.3 ALS
- 18.2.4 Huntington's
- 18.2.5 MS (Multiple Sclerosis)
-
18.3 Oceania Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 18.3.1 Hospitals
- 18.3.2 Clinics
- 18.3.3 Research Institutions
- 18.3.4 Long-term Care
- 18.3.5 Pharma R&D
- 18.4 Oceania Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 18.5 Oceania Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 18.6 Oceania Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 19 : MEA Neurodegenerative Disease Market Breakdown by Country, Type & Application
- 19.1 MEA Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 19.2.1 Alzheimer's
- 19.2.2 Parkinson's
- 19.2.3 ALS
- 19.2.4 Huntington's
- 19.2.5 MS (Multiple Sclerosis)
-
19.3 MEA Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 19.3.1 Hospitals
- 19.3.2 Clinics
- 19.3.3 Research Institutions
- 19.3.4 Long-term Care
- 19.3.5 Pharma R&D
- 19.4 MEA Neurodegenerative Disease Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 19.5 MEA Neurodegenerative Disease Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 19.6 MEA Neurodegenerative Disease Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Neurodegenerative Disease market may reach an estimated size of 112 Billion by 2032.
The Neurodegenerative Disease Market is growing at a CAGR of 8.70% over the forecasted period 2024 - 2032.
Development Of Monoclonal Antibody Therapeutics Targeting Amyloid Or Tau,Use Of Gene Therapy And Antisense Oligonucleotides,Exploration Of Microbiome–gut–brain Axis Therapies,Digital Biomarkers Via Wearables Monitoring Cognition And Movement,Combination Therapies That Address Multiple Pathologies. are seen to make big Impact on Neurodegenerative Disease Market Growth.
- Aging Demographics Driving Increased Alzheimer/Parkinson Prevalence
- Unsatisfactory Current Treatments Boosting Urget Need For Novel Therapies
- Advances In Biomarkers And Imaging For Early Detection
- Regulatory Incentives For Orphan And Rare Neurodegenerative Drugs
- Pharma R&D Focus On CNS Disorders.
Some of the major challanges seen in Global Neurodegenerative Disease Market are Blood–brain Barrier Remains A Major Delivery Hurdle,High Clinical Trial Failure Rates Creating Investment Risk,Need For Long-term Patient Monitoring For Efficacy And Safety,Complex Regulatory Requirements For Efficacy Demonstration,High Cost Of Therapy Development And Eventual Treatment..
Some of the opportunities that Analyst at HTF MI have identified in Neurodegenerative Disease Market are:
- Licensing Biomarker Tools To Pharma Partners
- Partnering For Early-detection Digital Diagnostic Platforms
- Launching Neurorehabilitation Remote-care Services
- Co-developing Combination Therapy Agent Platforms
- Applying Repurposed Drug Pipelines For Smaller Neurodegenerative Indications.
New entrants, including competitors from unrelated industries along with players such as Biogen (USA),Roche (Switzerland),Novartis (Switzerland),Pfizer (USA),Merck (USA),Eli Lilly (USA),Johnson & Johnson (USA),Sanofi (France),AbbVie (USA),GSK (UK),Eisai (Japan),Takeda (Japan),AC Immune (Switzerland),Amgen (USA),Alector (USA),Denali Therapeutics (USA),Neurocrine Biosciences (USA),Sage Therapeutics (USA),Alzheon (USA),Cassava Sciences (USA) Instituting a robust process in Global Neurodegenerative Disease Market.
Research paper of Global Neurodegenerative Disease Market shows that companies are making better progress than their supply chain peers –including suppliers, majorly in end-use applications such as Hospitals,Clinics,Research institutions,Long-term care,Pharma R&D.
The Global Neurodegenerative Disease Market Study is segmented by Alzheimer's,Parkinson's,ALS,Huntington's,MS (Multiple Sclerosis).
The Global Neurodegenerative Disease Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - Base year: 2024. Forecast period**: 2025 to 2032 [** unless otherwise stated]
The neurodegenerative disease market focuses on therapies, diagnostics, and care for progressive conditions like Alzheimer's, Parkinson's, ALS, and Huntington's disease. Characterized by the gradual deterioration of neurons, these disorders impact memory, movement, and cognitive function. With aging populations globally, demand for effective treatments, early diagnosis, and palliative care is rising. Current market offerings include symptomatic drugs, disease-modifying treatments, and assistive technologies. Biotech and pharma firms are investing in novel approaches, including monoclonal antibodies, gene therapies, and neuroprotective agents. The market is also seeing the integration of digital biomarkers, AI-based diagnostics, and brain imaging tools for earlier and more accurate detection. Challenges include high R&D costs, clinical trial failures, and the complex nature of neurodegeneration. Public-private partnerships and patient advocacy groups are influencing funding and research agendas. The neurodegenerative disease market represents a critical healthcare frontier with profound social and economic implications worldwide.
